Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation

Basit Öğe Kaydı
dc.contributor.authorMüderrisoğlu, Ahmet
dc.contributor.authorBabaoğlu, Elif
dc.contributor.authorKorkmaz, Elif Tuğçe
dc.contributor.authorOngun, Mert C.
dc.contributor.authorKarabulut, Erdem
dc.contributor.authorİskit, Alper B.
dc.contributor.authorEmri, Salih
dc.date.accessioned2021-01-14T18:10:20Z
dc.date.available2021-01-14T18:10:20Z
dc.date.issued2020
dc.departmentKKÜ
dc.descriptionMuderrisoglu, Ahmet/0000-0003-2954-360X
dc.description.abstractObjectives To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population. Methods 130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (n = 40), bupropion (n = 47), bupropion + NRT (n = 15), and varenicline (n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed. Results Cessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (p = 0.652, p = 0.328, respectively), or variants of CYP2B6 (p = 0.514, p = 0.779, respectively). Conclusion Genetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.en_US
dc.description.sponsorshipHacettepe University Research FundHacettepe University [TSA-2017-12810]en_US
dc.description.sponsorshipThis study was supported by Hacettepe University Research Fund (TSA-2017-12810).en_US
dc.identifier.citationMuderrisoglu, A., Babaoglu, E., Korkmaz, E. T., Ongun, M. C., Karabulut, E., İskit, A. B., ... Emri, S.(2020). Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. FRONTIERS IN GENETICS , vol.11.en_US
dc.identifier.doi10.3389/fgene.2020.571997
dc.identifier.issn1664-8021
dc.identifier.pmid33329709
dc.identifier.urihttps://doi.org/10.3389/fgene.2020.571997
dc.identifier.urihttps://hdl.handle.net/20.500.12587/12516
dc.identifier.volume11en_US
dc.identifier.wosWOS:000598127000001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFRONTIERS MEDIA SAen_US
dc.relation.ispartofFRONTIERS IN GENETICS
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectnicotineen_US
dc.subjectgenetic polymorphismen_US
dc.subjectaddictionen_US
dc.subjectP-glycoproteinen_US
dc.subjectcytochrome P450 enzymesen_US
dc.titleEffects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessationen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation.pdf
Boyut:
497.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu